![Sarah Burns BA (Hons)](https://profiles-cardiff.imgix.net/attachments/4955?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Miss Sarah Burns
(she/her)
BA (Hons)
Teams and roles for Sarah Burns
Research Associate
Publication
2025
- Russell, N. H. et al., 2025. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology 43 (6), pp.694-704. (10.1200/JCO.24.00259)
2022
- Freeman, S. D. et al., 2022. A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results. Blood 140 (S1), pp.532-533. (10.1182/blood-2022-162245)
2017
- Burnett, A. K. et al. 2017. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia 31 (2), pp.310-317. (10.1038/leu.2016.225)
2009
- Griffiths, G. O. et al. 2009. Fragmatic: a randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC Cancer 9 , pp.355-363. (10.1186/1471-2407-9-355)
- Macbeth, F. R. et al., 2009. Interim safety data on the FRAGMATIC trial: a randomised phase III clinical trial investigating the effect of FRAGMin® added to standard therapy in patients with lung cancer [Abstract]. Journal of Thoraric Oncology 4 (9), pp.S5-S968. (10.1097/JTO.0b013e3181b9c77e)
Articles
- Burnett, A. K. et al. 2017. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia 31 (2), pp.310-317. (10.1038/leu.2016.225)
- Freeman, S. D. et al., 2022. A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results. Blood 140 (S1), pp.532-533. (10.1182/blood-2022-162245)
- Griffiths, G. O. et al. 2009. Fragmatic: a randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC Cancer 9 , pp.355-363. (10.1186/1471-2407-9-355)
- Macbeth, F. R. et al., 2009. Interim safety data on the FRAGMATIC trial: a randomised phase III clinical trial investigating the effect of FRAGMin® added to standard therapy in patients with lung cancer [Abstract]. Journal of Thoraric Oncology 4 (9), pp.S5-S968. (10.1097/JTO.0b013e3181b9c77e)
- Russell, N. H. et al., 2025. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology 43 (6), pp.694-704. (10.1200/JCO.24.00259)